Edition:
United States

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

49.90SEK
15 Dec 2017
Change (% chg)

-0.10kr (-0.20%)
Prev Close
50.00kr
Open
50.25kr
Day's High
50.75kr
Day's Low
49.70kr
Volume
56,345
Avg. Vol
65,592
52-wk High
102.00kr
52-wk Low
47.20kr

Summary

Name Age Since Current Position

Anna Malm Bernsten

56 2016 Independent Chairman of the Board

Christine Lind

43 2017 President, Chief Executive Officer

Ola Burmark

48 2015 Chief Financial Officer

Asa Holmgren

52 Executive Vice President Strategic Regulatory Affairs and Market Access

Daniel Eriksson

42 2016 Chief Information Officer

Richard Bethell

54 2016 Chief Scientific Officer

John Ohd

46 2017 Chief Medical Officer

Anders Hallberg

72 2012 Director

Bengt Julander

64 2017 Director

Stina Lundgren

38 2016 Director, Employee Representative

Bengt Westermark

72 2017 Director

Anders Ekblom

62 2014 Independent Director

Helena Levander

60 2015 Independent Director

Biographies

Name Description

Anna Malm Bernsten

Ms. Anna Malm Bernsten has been Independent Chairman of the Board of Directors of Medivir AB since May 3, 2016. She has been Independent Director of the Company since 2006. She is also Member of the Company's Audit Committee, Nomination Committee and R&D Committee. She has knowledge of the life sciences sector and runs her own management and business development company. Anna has extensive experience as a director of listed and unlisted companies and operational experience from leading positions in Pharmacia, ASSA ABLOY, GE Healthcare Life Sciences, Medivir and Baxter Medical, as well as President and Chief Executive Officer of Carmeda AB. She is currently Chairman of the Board of Directors of the CEBA/Oatly AB and Bjorn Axen and Member of the Board of Directors of Arcam, Cellavision AB, Neurovive AB, Pagengruppen. She was previously Member of the Board of Directors of the Medivir acquired BioPhausia AB. She holds a Master of Science degree in Engineering with a major chemical technology, organic chemistry and analytical chemistry.

Christine Lind

Ms. Christine Lind has been appointed President and Chief Executive Officer of Medivir AB effective as of April 1, 2017. She has previously served as Executive Vice President Strategic Business Development at the Company since March 1, 2015. Her most recent position was as Vice President, Business Development at LifeCell Corporation in New York, and she also has twelve years of investment banking experience at Merrill Lynch & Co. and Gerard Klauer Mattison & Co. Christine holds Bachelor of Science in Finance and Information Systems at New York University and also has a Master of Business Administration from Columbia Business School.

Ola Burmark

Mr. Ola Burmark is no longer Chief Financial Officer of Medivir AB., effective on January 3, 2018. Previously, he was Chief Financial Officer at OneMed AB and Aditro Holding AB. He has also worked as SVP Finance and Mergers & Acquisitions at Thule Group AB and Cell Network AB, as Cash Manager at AB SCA Finans, and as an auditor at Ernst & Young. Ola holds Bachelor of Science in Finance and Business Administration.

Asa Holmgren

Ms. Asa Holmgren serves as Executive Vice President Strategic Regulatory Affairs and Market Access at Medivir Aktiebolag. She has been employed since 2015. She holds M. Sc. in Pharmacy, trained at Uppsala University. She is former Head of Regulatory Affairs at Orexo AB. She has experience from a number of large pharmaceutical companies, including 12 years as Senior Global Regulatory Affairs Director at AstraZeneca, and, in particular, international, strategic duties within Regulatory Affairs. Asa has also worked for AstraZeneca in Canada and Japan.

Daniel Eriksson

Mr. Daniel Eriksson has been Chief Information Officer at Medivir Aktiebolag since 2016. He holds Ph.D. from Coventry University, B.Sc. in Systems Science from Linkoping University. He is former Technical Director for G4S Risk Management, India Country Manager for Hill & Associates, e-Governance advisor for Iraqi authorities, CIO for the UN OPS Kosovo mission, as well as a series of positions with the UN and international organizations in roles relating to IT, security, decision support systems, innovation, and digitalization.

Richard Bethell

Mr. Richard Bethell has been Chief Scientific Officer at Medivir AB since 2016. He has been Executive Vice President Research & Development at the Company since 2015. He has previously been Executive Vice President Discovery Research at the Company since April 22, 2013. He has a background within drug discovery and development, with nearly 25 years of experience from the pharmaceutical industry. He joined the Company from Boehringer Ingelheim (Canada) Ltd., where he was employed as Director of Biological Sciences. He also served as Director of Therapeutic Research at Shire and various positions at Pfizer Global and Group Manager, GlaxoSmithKline. He holds a Doctorate of Philosophy degree Chemistry from the University of Oxford, the United Kingdom.

John Ohd

Mr. John Ohd, M.D., Ph.D. has served as Chief Medical Officer at Medivir AB since June 19, 2017. He has previously been Medivir's Director, Clinical Research & Development since 2014, prior to which he was senior director of Experimental Medicine at Shire in Nyon, Switzerland. John has held various positions at AstraZeneca in Sodertalje, Sweden, including group director for early development in cognitive and neurodegenerative disorders. He worked in cancer research initially at Lund University where he received a Ph.D. in Experimental Pathology and subsequently at Karolinska Institute. John received his M.D. from Linkoping University, and trained clinically at Karolinska University Hospital.

Anders Hallberg

Mr. Anders R Hallberg has served as Member of the Board of Directors of Medivir AB since May 10, 2012. He is Chairman of the Company’s Research and Development Committee. He has held a professorship in Medicinal Chemistry at Uppsala University’s Faculty of Pharmacy since 1990 and has also held a number of positions as scientific advisor at AstraZeneca and smaller pharmaceutical companies between 1990 and 2006. Prior to this, he was the Head of the Medicinal Chemistry Department at Astra in Lund. Between 2006 and 2011 he was the Vice Chancellor of Uppsala University. He has published over 280 scientific articles, a number of which are on the subject of pharmaceuticals for infectious diseases, and is co-inventor of a number of granted patents. He is Member of the Royal Swedish Academy of Sciences, and the Royal Swedish Academy of Engineering Sciences. He has also been awarded honorary doctorates in Sweden and other countries. He is Member of the Boards of foundations and universities.

Bengt Julander

Mr. Bengt Julander has been Director of Medivir Aktiebolag since May 3, 2017. He is Pharmacist and has worked in the pharmaceutical industry since 1978. He has been CEO of Linc AB, which invests in life sciences. Since 1990, he has primarily been active as an investor in and a Member of the Boards of pharmaceutical development companies. He has experience of developing and commercializing products. He is Member of the Boards of Bringwell AB, Linc AB, Livland Skog AB, Pharmalink AB, Proequo AB, Sedana Medical AB, Stille AB and Swevet AB, and a number of smaller companies.

Stina Lundgren

Ms. Stina Lundgren has been Director, Employee Representative at Medivir Aktiebolag since November 2016. She has been Deputy Director since 2013. She has been appointed by the Unionen trade union. She holds Ph.D. in Chemistry from KTH Royal Institute of Technology. She was employed in 2008 as a Senior Research Scientist in the Chemistry Department.

Bengt Westermark

Mr. Bengt Westermark has been Director of Medivir Aktiebolag since May 3, 2017. He is Professor of Tumor Biology at Uppsala University, the Faculty of Medicine, since 1986. He was Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. He was Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. He has been Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organization, and the European Academy of Cancer Sciences. He has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers. He is Member of the Board of Hamlet Pharma AB and a variety of advisory groups for medical research financing.

Anders Ekblom

Dr. Anders Ekblom has been Independent Member of the Board of Directors of Medivir AB since May 8, 2014. He is Member of the Company's Research and Development (since May 2014) and Audit Committees. He is physician (specializing in anesthesia and intensive care), dentist, Doctor of Medicine and Associate Professor in physiology at the Karolinska Institute. He has previously worked at AstraZeneca for 19 years in a number of different positions, including Executive Vice President Global Medicines Development, and Chief Executive Officer of AstraZeneca AB in Sweden. He is currently Chairman of the Board of the Karolinska University Hospital and TFS International AB, as well as Member of the Board of Directors of the Swedish Research Council, SwedenBio, AnaMar AB, Infant Bacterial Therapeutics AB, Mereo Biopharma Ltd, RSPR Pharma AB and Viscogel AB and is a senior advisor for Phase4 Partners, UK.

Helena Levander

Ms. Helena Levander has been Independent Director of Medivir AB since May 5, 2015. She holds B.Sc. in Economics & Business Administration from the Stockholm School of Economics. She is also Chairman of Company Audit Committee and Member of Remuneration Committee. She is Founder and now Chairman of the Board of Nordic Investor Services AB. Helena has many years’ experience of the financial and equities market and of corporate governance issues, and her CV includes positions at Neonet, Odin Forvaltning, Nordea Asset Management and SEB Asset Management. She is Member of the Boards of Concordia Maritime AB, Recipharm AB, NeuroVive Pharmaceutical AB and Stampen AB, and is a former Member of the Boards of, amongst others, Gant AB, Transatlantic AB, Nordisk Energiforvaltning ASA, Svensk Exportkredit AB (SEK), Bure Equity AB, Mandator AB, Geveko AB, Erik Penser Bankaktiebolag and SBAB Bank AB.